Topic: How To Invest


In 2017, mutual funds face increasing competition from ETFs as a low-cost alternative. But here’s a look back at a fund that continues to attract the same interest as it did here in May 2009…

TD HEALTH SCIENCES FUND $13.54 (CWA Rating: Speculative) (TD Asset Management, P.O. Box 7500, Station A, Toronto, Ontario M5W 1P9. 1-800-463-3863; Web site: No load — deal directly with the bank) mainly invests in large-capitalization health-care stocks and earlier-stage biotechnology shares in the U.S. The fund’s managers believe these firms will benefit from increased health spending spurred by an aging population.

TD Health Sciences Fund’s top holdings include Gilead Sciences, Alexion Pharmaceuticals, Teva Pharmaceutical, Baxter International, Vertex Pharmaceuticals, Medco Health Solutions, Wyeth, Roche Holdings, Henry Schein Inc. and Cephalon.

TD Health Sciences Fund lost about 23.6% over the year ended March 31, 2009. However, a rise in the U.S. dollar cut that loss to 3.6% in Canadian dollars, compared to a loss of 24.1% for the S&P 500 (also in Canadian funds). The fund’s MER is 2.68%.

TD Health Sciences Fund is still a buy.

Comments are closed.